ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”

ASCO launches health equity learning collaborative

The American Society of Clinical Oncology has brought together 12 groups of cancer care delivery professionals to initiate a program aimed to improve health equity.

August 02, 2024

Vol.50 No.31

Letter To The Editor

Tweaking the existing systems is not the answer to drug shortages

In the July 19 article “Platinum drugs are off the shortage list, but the underlying problem is unsolved,” FDA Commissioner Robert Califf and others describe a solution to the U.S. drug shortage as a matter of paying more for generic drugs.

July 26, 2024

Vol.50 No.30

Clinical Trials & Tribulations

Better oncology drug management could lead to improved outcomes, lower costs

Cancer treatment is steadily improving. The proof can be found in the number of patients with cancer living longer than ever before. Over the next decade, the number of people who have lived five or more years after their diagnosis is projected to increase approximately 30% to 16.3 million.

July 26, 2024

Vol.50 No.30

By Matt Ingram

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.

Oncology providers, advocates form LGBTQ+ community group at ASCO with focus on research, education, equity

“When I joined ASCO in 2001, the most important thing to me was networking. I savored the opportunities to come to the annual meeting to meet and to talk with those who had led the studies that would inform standards of care, particularly in gynecologic oncology,” said Don S. Dizon.

June 21, 2024

Vol.50 No.25

By Don S. Dizon, Chunkit Fung, Paula Chambers Raney, Charles Kamen and Shail Maingi

Clinical

Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

Treatment with an indefinite course of osimertinib dramatically improves progression-free survival for patients with stage 3 non-small cell cancer, according to the results of the LAURA trial. The median PFS was 39.1 months in the osimertinib group, compared to 5.6 months with the placebo group.

June 07, 2024

Vol.50 No.23

By Jacquelyn Cobb and McKenzie Prillaman

ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”

YOU MAY BE INTERESTED IN

ASCO launches health equity learning collaborative

Tweaking the existing systems is not the answer to drug shortages

Better oncology drug management could lead to improved outcomes, lower costs

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Oncology providers, advocates form LGBTQ+ community group at ASCO with focus on research, education, equity

Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

Renew today!

Subscriber content

Login

ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”

YOU MAY BE INTERESTED IN

ASCO launches health equity learning collaborative

Tweaking the existing systems is not the answer to drug shortages

Better oncology drug management could lead to improved outcomes, lower costs

Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Oncology providers, advocates form LGBTQ+ community group at ASCO with focus on research, education, equity

Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

Login

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”